YHR070C-A Antibody

What is YHR070C-A and why are antibodies against it valuable in yeast research?

YHR070C-A is a putative uncharacterized protein in Saccharomyces cerevisiae (strain ATCC 204508 / S288c), commonly known as baker's yeast. Antibodies against this protein are valuable for studying its expression, localization, and function within the yeast proteome . As a research tool, these antibodies allow detection of the protein in various experimental contexts, facilitating investigations into yeast biology, genetics, and biochemistry.

When using YHR070C-A antibodies in research, consider:

• The protein's uncharacterized nature means antibodies are crucial for initial characterization studies

• Detection can be optimized across multiple experimental platforms including Western blotting and ELISA

• Cross-reactivity profiles should be evaluated when studying related yeast strains

What are the recommended storage conditions for YHR070C-A antibodies?

YHR070C-A antibodies should be stored at -20°C or -80°C upon receipt to maintain functionality. Repeated freeze-thaw cycles should be avoided to preserve antibody integrity . The typical storage buffer consists of:

For optimal research results, aliquot the antibody upon receipt to minimize freeze-thaw cycles and maintain a consistent testing environment across experiments .

What applications are YHR070C-A antibodies validated for?

YHR070C-A antibodies have been validated primarily for ELISA and Western Blot applications, with specific optimization for identifying the antigen in Saccharomyces cerevisiae strain ATCC 204508 / S288c . When integrating these antibodies into research protocols:

• ELISA applications: Useful for quantitative detection of YHR070C-A in solution

• Western Blot applications: Effective for detecting the protein in cell lysates and confirming molecular weight

• Immunoprecipitation: May require additional validation before use

Researchers should perform validation studies when applying these antibodies to novel experimental contexts or when working with modified yeast strains with altered YHR070C-A expression .

What strategies can resolve cross-reactivity issues with YHR070C-A antibodies in complex yeast protein mixtures?

When working with YHR070C-A antibodies in complex yeast extracts, researchers may encounter cross-reactivity challenges. Advanced troubleshooting approaches include:

• Pre-absorption technique: Incubating the antibody with lysates from YHR070C-A knockout strains to remove antibodies that bind to other epitopes

• Epitope mapping: Identifying the specific regions of YHR070C-A recognized by the antibody to predict potential cross-reactivity

• Competitive binding assays: Using recombinant YHR070C-A protein to compete for antibody binding

For optimal specificity in Western blot applications, consider this optimization protocol:

These approaches are particularly important when studying YHR070C-A in the context of other yeast proteins with similar structural features or when examining protein-protein interactions .

How can researchers validate YHR070C-A antibody specificity in knockout models?

For rigorous validation of YHR070C-A antibody specificity, a gold-standard approach utilizes gene knockout models. The methodological workflow includes:

• Generate YHR070C-A knockout strains using established yeast genetic techniques

  • One-step gene replacement with selection markers (e.g., LEU2)

  • CRISPR-Cas9 mediated deletion

  • Plasmid shuffle approaches for essential genes

• Perform parallel Western blot analyses using standardized loading controls

• Confirm specificity by demonstrating signal presence in wild-type and absence in knockout samples

When performing knockout validation, researchers should note that YLR136C gene deletion in S. cerevisiae can be generated by one-step replacement with a LEU2 marker cassette, and validated by RT-qPCR with specific primers (e.g., qRB007 and qRB008) .

How should researchers optimize ELISA protocols for YHR070C-A detection?

ELISA optimization for YHR070C-A detection requires careful attention to multiple parameters. The following protocol adjustments can enhance sensitivity and specificity:

• Coating optimization:

  • Buffer comparison: Carbonate buffer (pH 9.6) vs. PBS (pH 7.4)

  • Concentration titration: Test 1-10 μg/mL of capturing antibody

  • Incubation time: Compare overnight at 4°C vs. 2 hours at room temperature

• Blocking optimization:

  • Compare BSA (1-5%) vs. non-fat milk (1-5%)

  • Add 0.05% Tween-20 to reduce background

• Sample preparation:

  • For cell lysates: Standardize protein extraction methods

  • For purified protein: Use serial dilutions for standard curve generation

• Detection system optimization:

  • Primary antibody dilution: Test ranges from 1:500 to 1:5000

  • Secondary antibody selection: HRP vs. AP conjugates

  • Substrate selection: TMB, ABTS, or pNPP based on sensitivity requirements

When developing a new ELISA protocol, researchers should perform validation studies including:

• Positive and negative controls (YHR070C-A expressing and non-expressing samples)

• Specificity tests with competitive binding

• Reproducibility assessment across different lots of antibody

What strategies can improve YHR070C-A antibody stability and longevity in research applications?

Maximizing YHR070C-A antibody stability requires attention to storage and handling conditions throughout the research workflow. Advanced stability enhancement strategies include:

• Storage optimization:

  • Aliquot into single-use volumes upon receipt

  • Add stabilizing agents: Additional 0.1% BSA for diluted working solutions

  • Consider lyophilization for long-term archiving

• Buffer formulation:

  • Test modified storage buffers with varied glycerol concentrations (20-50%)

  • Evaluate alternative preservatives to Proclin 300 if interference occurs

  • Optimize pH stability range (typically 7.2-7.6)

• Stability monitoring:

  • Implement quality control testing at regular intervals

  • Compare functional activity using standardized assays

  • Document lot-to-lot variation

For extended shelf-life, researchers should consider evaluating different storage buffers and additives through accelerated stability studies at elevated temperatures .

How does antibody response to YHR070C-A compare with other S. cerevisiae antibodies in immunological studies?

When examining YHR070C-A in the context of broader yeast immunology research, it's important to understand the comparative antibody responses. Unlike anti-Saccharomyces cerevisiae antibodies (ASCA) that have been extensively studied in clinical contexts, antibody responses to specific yeast proteins like YHR070C-A may exhibit different kinetics and characteristics.

Research comparing antibody stability and durability shows:

• ASCA titers remain remarkably stable over time in both experimental and clinical settings

• In murine models, colitis does not significantly enhance ASCA production despite barrier impairment

• Formal immunization with yeast mannans plus adjuvant is required for significant antibody titer increases

When designing immunological studies involving YHR070C-A:

• Consider the stability of antibody responses over experimental timeframes

• Account for potential strain-specific differences in immunogenicity

• Include appropriate controls to distinguish specific from non-specific responses

Research with ASCA suggests that antibody responses to yeast components are largely genetically predetermined rather than environmentally induced, which may have implications for YHR070C-A antibody development and application strategies .

What advanced approaches can improve YHR070C-A antibody affinity and specificity through directed evolution?

Recent advancements in antibody engineering provide powerful tools for enhancing YHR070C-A antibody characteristics. Implementing directed evolution strategies can significantly improve affinity, specificity, and stability through iterative selection processes.

The state-of-the-art Autonomous Hypermutation yEast surfAce Display (AHEAD) system represents a particularly promising approach:

• System components:

  • OrthoRep system for rapid hypermutation (mutation rates up to ~10^-4 substitutions per base)

  • Yeast surface display of antibody fragments

  • Selection through fluorescence-activated cell sorting (FACS)

• Key advantages:

  • β-estradiol induction achieves faster display (hours vs. 48 hours for galactose)

  • Continuous diversification during culture growth

  • No reformatting required between selection and characterization

This approach has demonstrated success in evolving nanobodies against challenging targets, yielding variants with 5-6 mutations and significantly improved binding characteristics after just six cycles of evolution .

How can researchers interpret contradictory results between different antibody-based detection methods for YHR070C-A?

When facing discrepancies between different antibody-based detection methods for YHR070C-A, researchers should follow a systematic troubleshooting and interpretation approach:

• Method-specific limitations assessment:

  Method	Native State Preservation	Sensitivity Range	Potential Interference
  ELISA	Moderate (depends on coating)	ng/mL range	Sample matrix effects
  Western Blot	Denatured (SDS-PAGE)	Low ng range	Reducing agents, fixatives
  Immunoprecipitation	Native (non-denaturing)	Variable	Protein complexes, PTMs
  Flow Cytometry	Native (surface exposure)	Moderate	Autofluorescence

• Systematic validation protocol:

  • Perform reciprocal validation across methods

  • Include positive and negative controls in all experiments

  • Test multiple antibody concentrations and incubation conditions

  • Evaluate epitope accessibility under different experimental conditions

• Advanced reconciliation approaches:

  • Epitope mapping to identify method-specific limitations

  • Competitive binding assays to confirm specificity

  • Mass spectrometry validation of protein identity

  • Genetic approaches (knockdown/overexpression) to confirm target specificity

• Data integration framework:

  • Establish a hierarchy of evidence based on method reliability

  • Consider the possibility of detecting different protein isoforms or modified forms

  • Document experimental conditions that influence detection consistency

When discrepancies persist, consider that YHR070C-A, as a putative uncharacterized protein, may undergo context-dependent modifications or interactions that affect epitope accessibility or antibody recognition in different experimental contexts .

How does the study of YHR070C-A antibodies contribute to broader yeast research frameworks?

Research utilizing YHR070C-A antibodies contributes to multiple dimensions of yeast biology and has broader implications for biochemical research:

• Proteome characterization: As an uncharacterized protein, YHR070C-A investigation contributes to completing the functional annotation of the yeast proteome, which serves as a model for eukaryotic systems

• Method development: Techniques optimized for YHR070C-A antibody applications often translate to other challenging yeast proteins

• Evolutionary insights: Comparative studies of YHR070C-A across yeast strains provide insights into protein conservation and diversification

• Technology platform advancement: YHR070C-A serves as a target for validating new antibody engineering approaches like yeast surface display

The antibody-based research on YHR070C-A connects to multiple experimental frameworks in yeast biology:

Future investigations will likely focus on integrating antibody-based detection with emerging technologies like spatial proteomics and single-cell analysis to fully elucidate YHR070C-A function .

What methodological considerations should guide researchers when adapting yeast antibody protocols from other systems to YHR070C-A studies?

When translating antibody methodologies from other yeast proteins to YHR070C-A research, several critical adaptation considerations must be addressed:

• Strain-specific optimization:

  • S288c strain background may require different extraction conditions than other common lab strains

  • Growth conditions significantly impact protein expression levels

  • Cell wall composition varies between strains, affecting extraction efficiency

• Technical challenges specific to YHR070C-A:

  • Putative uncharacterized status means protein characteristics are less defined

  • Expression levels may be condition-dependent

  • Cross-reactivity potential with related proteins requires careful validation

• Controls and standards development:

  • Generate recombinant YHR070C-A as positive control

  • Develop standardized lysate preparations

  • Establish knockout strains as negative controls

Researchers should follow the yeast strain construction methods detailed in search result #2, which provides comprehensive guidance on genetic techniques in S. cerevisiae, including one-step gene replacement with marker cassettes and PCR validation approaches .

What emerging technologies might enhance future studies of YHR070C-A using antibody-based approaches?

Several cutting-edge technologies are poised to transform YHR070C-A antibody research in the coming years:

• Single-molecule imaging techniques:

  • Super-resolution microscopy for precise localization studies

  • Single-molecule FRET to examine protein-protein interactions

  • Live-cell tracking of YHR070C-A dynamics

• Advanced protein engineering platforms:

  • Machine learning-guided antibody optimization

  • Synthetic biology approaches to antibody design

  • AHEAD system with increased mutation rates (e.g., "BadBoy3" polymerase with 10-fold higher error rates)

• Integrated multi-omics approaches:

  • Combining antibody-based detection with transcriptomics

  • Spatial proteomics using antibody-based proximity labeling

  • Systems biology modeling of YHR070C-A function

These technologies will enable more comprehensive characterization of YHR070C-A's function, interactions, and regulation, potentially revealing its role in previously unexplored cellular contexts or environmental conditions .